Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives
Top Cited Papers
Open Access
- 1 January 2016
- journal article
- review article
- Published by The Korean Academy of Tuberculosis and Respiratory Diseases in Tuberculosis and Respiratory Diseases
- Vol. 79 (2), 74-84
- https://doi.org/10.4046/trd.2016.79.2.74
Abstract
Nontuberculous mycobacteria (NTM) are emerging pathogens that affect both immunocompromised and immunocompetent patients. The incidence and prevalence of NTM lung disease are increasing worldwide and rapidly becoming a major public health problem. For the diagnosis of NTM lung disease, patients suspected to have NTM lung disease are required to meet all clinical and microbiologic criteria. The development of molecular methods allows the characterization of new species and NTM identification at a subspecies level. Even after the identification of NTM species from respiratory specimens, clinicians should consider the clinical significance of such findings. Besides the limited options, treatment is lengthy and varies by species, and therefore a challenge. Treatment may be complicated by potential toxicity with discouraging outcomes. The decision to start treatment for NTM lung disease is not easy and requires careful individualized analysis of risks and benefits. Clinicians should be alert to those unique aspects of NTM lung disease concerning diagnosis with advanced molecular methods and treatment with limited options. Current recommendations and recent advances for diagnosis and treatment of NTM lung disease are summarized in this article.Keywords
This publication has 100 references indexed in Scilit:
- Treatment of Refractory Mycobacterium avium Complex Lung Disease with a Moxifloxacin-Containing RegimenAntimicrobial Agents and Chemotherapy, 2013
- Synergistic activities of tigecycline with clarithromycin or amikacin against rapidly growing mycobacteria in TaiwanInternational Journal of Antimicrobial Agents, 2013
- In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial DiseaseAntimicrobial Agents and Chemotherapy, 2012
- Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm (41) and rrl SequencingAntimicrobial Agents and Chemotherapy, 2011
- Multilocus Sequence Analysis and rpoB Sequencing of Mycobacterium abscessus (Sensu Lato) StrainsJournal of Clinical Microbiology, 2011
- Inaccuracy of Single-Target Sequencing for Discriminating Species of the Mycobacterium abscessus GroupJournal of Clinical Microbiology, 2009
- Cohort Study of Molecular Identification and Typing of Mycobacterium abscessus, Mycobacterium massiliense , and Mycobacterium bolletiiJournal of Clinical Microbiology, 2009
- A Novel Gene,erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates ofMycobacterium abscessusbut Is Absent fromMycobacterium chelonaeAntimicrobial Agents and Chemotherapy, 2009
- rpoB sequence-based identification of Mycobacterium avium complex speciesMicrobiology, 2008
- Pulmonary Nontuberculous Mycobacterial DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2008